Results 11 to 20 of about 6,922 (185)

Mapping benefit, risk, and opportunity in PAD4 inhibition

open access: yesFrontiers in Immunology
Peptidylarginine deiminase 4 (PAD4) is increasingly targeted to modulate inflammatory pathology, yet its inhibition produces biological effects that extend beyond the processes it was originally designed to suppress. While PAD4 targeting has largely been
Caio Santos Bonilha   +2 more
doaj   +4 more sources

Neutrophil Extracellular Traps: From Mechanistic Insights to Therapeutic Targeting. [PDF]

open access: yesMedComm (2020)
Neutrophil extracellular traps act as multimodal signal processors in cancer via three mechanisms: biomechanical scaffolds activating integrin–FAK signaling and excluding immune cells; immunometabolic hubs driving glycolysis and immunosuppression; and signal‐integration platforms synergistically activating oncogenic pathways.
Fan H   +5 more
europepmc   +2 more sources

C3a-C3aR Signaling Modulates Neutrophil Extracellular Traps Formation and Contributes to Blood-Brain Barrier Injury After Stroke. [PDF]

open access: yesCNS Neurosci Ther
Following ischemic stroke, C3a‐C3aR signaling was associated with increased neutrophil extracellular traps (NETs) formation, blood–brain barrier (BBB) disruption, and neurological impairment. Pharmacological modulation of C3a‐C3aR signaling or NETs formation attenuated BBB injury and improved neurological outcomes, supporting a potential role of C3a ...
Zhang Q   +7 more
europepmc   +2 more sources

Serum anti-PAD4 autoantibodies are present in cystic fibrosis children and increase with age and lung disease severity

open access: yesAutoimmunity, 2022
Cystic fibrosis (CF) lung disease begins early in childhood and is characterized by neutrophilic inflammation of the airways. Neutrophil extracellular traps (NETs) represent one mechanism by which neutrophils contribute to lung damage.
Rachel W. Linnemann   +5 more
doaj   +1 more source

SAG101 forms a ternary complex with EDS1 and PAD4 and is required for resistance signaling against turnip crinkle virus. [PDF]

open access: yesPLoS Pathogens, 2011
EDS1, PAD4, and SAG101 are common regulators of plant immunity against many pathogens. EDS1 interacts with both PAD4 and SAG101 but direct interaction between PAD4 and SAG101 has not been detected, leading to the suggestion that the EDS1-PAD4 and EDS1 ...
Shifeng Zhu   +6 more
doaj   +1 more source

Autocitrullination confers monocyte chemotactic properties to peptidylarginine deiminase 4

open access: yesScientific Reports, 2023
Peptidylarginine deiminase 4 (PAD4) contributes to the production of citrullinated proteins as autoantigens for anti-citrullinated protein antibodies (ACPAs) in rheumatoid arthritis (RA). PAD4 can also self-deiminate via autocitrullination.
Ken Yoshida   +6 more
doaj   +1 more source

A single-dose PLGA encapsulated protective antigen domain 4 nanoformulation protects mice against Bacillus anthracis spore challenge. [PDF]

open access: yesPLoS ONE, 2013
Bacillus anthracis, the etiological agent of anthrax, is a major bioterror agent. Vaccination is the most effective prophylactic measure available against anthrax. Currently available anthrax vaccines have issues of the multiple booster dose requirement,
Manish Manish   +4 more
doaj   +1 more source

Anti-peptidylarginine deiminase-4 antibodies at mucosal sites can activate peptidylarginine deiminase-4 enzyme activity in rheumatoid arthritis

open access: yesArthritis Research & Therapy, 2021
Background Mucosal sites are hypothesized to play a role in the development of rheumatoid arthritis (RA). Since serum anti-peptidylarginine deiminase (PAD)4 antibodies, including a subset that cross-react with PAD3 (PAD3/4), are specific for RA and ...
M. Kristen Demoruelle   +8 more
doaj   +1 more source

Profiling Protein Arginine Deiminase 4 (PAD4): A novel screen to identify PAD4 inhibitors [PDF]

open access: yesBioorganic & Medicinal Chemistry, 2008
Protein Arginine Deiminase 4 (PAD4) has emerged as a leading target for the development of a Rheumatoid Arthritis (RA) pharmaceutical. Herein, we describe the development of a novel screen for PAD4 inhibitors that is based on a PAD4-targeted Activity-Based Protein Profiling reagent, denoted Rhodamine-conjugated F-Amidine (RFA).
Knuckley, Bryan   +2 more
openaire   +3 more sources

Anti-PAD4 antibodies link autoimmunity to PAD4 with CTL-associated rheumatoid arthritis. [PDF]

open access: yesAnn Rheum Dis
We aimed to study the serologic, genetic, and immunologic underpinnings associated with cytotoxic T lymphocytes (CTLs) in rheumatoid arthritis (RA), using T-large granular lymphocytic leukaemia with comorbid RA (T-LGLL/RA) as a model of CTL-linked RA.We used blood samples and paired clinical data from patients with RA, T-LGLL/RA, T-LGLL and healthy ...
Ananth K   +17 more
europepmc   +4 more sources

Home - About - Disclaimer - Privacy